Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2007

PTC and Spinal Muscular Atrophy Foundation Extend Agreement

  • PTC Therapeutics and the Spinal Muscular Atrophy Foundation agreed to expand their research collaboration to identify and characterized compounds to treat the disease.

    PTC will receive an additional $1.6 million in funding when certain milestone considerations are met.

    The partnerhip is focusing on candidates to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA.

    “By applying our proprietary technologies,” says Stuart W. Peltz, Ph.D., president and CEO of PTC, “we have made important progress in our efforts to identify treatments for SMA.”



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »